DANYELLE DINGLE: Open Payments
NPI 1497202584 · SURPRISE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$989 in 50 payments from 16 companies in 2025. Trend: 2023 $1,078 · 2024 $21 · 2025 $989
Food & beverage: $989
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $189 |
| Lilly USA, LLC | 10 | $134 |
| Lundbeck LLC | 5 | $92 |
| Novo Nordisk Inc | 5 | $92 |
| Aimmune Therapeutics, Inc. | 3 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $69 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $58 |
| Almatica Pharma LLC | 2 | $54 |
| ABBVIE INC. | 2 | $47 |
| Boston Scientific Corporation | 1 | $36 |
Products named: REXULTI, FARXIGA, ZENPEP, CAPLYTA, TERIPARATIDE, KISUNLA, Ozempic, Rybelsus.
Industry payments across AZ — which companies pay providers there.
